Synthetic lethality in cancer drug discovery: challenges and opportunities

Area of Science:

• Oncology
• Genetics
• Drug Discovery

Background:

• Synthetic lethality is a promising strategy for targeted cancer therapy.
• Clinical success of PARP inhibitors in BRCA-mutant cancers validates the concept.
• Translation of other synthetic lethal interactions into therapies has been slow due to challenges in drug development and the context-specific nature of these interactions.

Purpose of the Study:

• To review recent advances in the discovery and validation of synthetic lethal pairs.
• To discuss novel approaches for identifying and developing synthetic lethal therapies.
• To highlight how new technologies are refining the synthetic lethality paradigm for cancer treatment.

Main Methods:

• Large-scale genetic screens for initial discovery.
• CRISPR-based approaches including combinatorial screens, base editing, and saturation mutagenesis for novel interaction discovery.
• Machine learning models for prioritizing candidate pairs and identifying biomarkers.
• High-content imaging and single-cell profiling for detailed phenotypic analysis.

Main Results:

• Recent advances are accelerating the discovery of synthetic lethal interactions.
• CRISPR and machine learning offer powerful tools for identifying and validating new targets.
• Advanced phenotypic readouts provide deeper insights into cellular responses beyond simple fitness.

Conclusions:

• Developments in discovery and validation are refining the synthetic lethality paradigm.
• These advances hold significant potential for developing novel targeted cancer therapies.
• Interdisciplinary approaches are crucial for translating synthetic lethality into effective clinical treatments.